| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RPA4 |
| Uniprot No | Q13156 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-260aa |
| 氨基酸序列 | MSKSGFGSYGSISAADGASGGSDQLCERDATPAIKTQRPKVRIQDVVPCNVNQLLSSTVFDPVFKVRGIIVSQVSIVGVIRGAEKASNHICYKIDDMTAKPIEARQWFGREKVKQVTPLSVGVYVKVFGILKCPTGTKSLEVLKIHVLEDMNEFTVHILETVNAHMMLDKARRDTTVESVPVSPSEVNDAGDNDESHRNFIQDEVLRLIHECPHQEGKSIHELRAQLCDLSVKAIKEAIDYLTVEGHIYPTVDREHFKSA |
| 预测分子量 | 32.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于RPA4重组蛋白的模拟参考文献示例(实际文献需通过学术数据库验证)：
---
1. **文献名称**：*Functional characterization of recombinant human RPA4 in DNA repair pathways*
**作者**：Mason, A.C., et al. (2019)
**摘要**：本研究通过重组表达人源RPA4蛋白，发现其与RPA复合物其他亚基(如RPA1/RPA2)的相互作用较弱，可能通过竞争性结合调控DNA损伤修复效率，尤其在电离辐射响应中表现出独特的抑制效应。
2. **文献名称**：*Overexpression of RPA4 in cancer cells alters chemotherapeutic sensitivity*
**作者**：Deng, X., et al. (2020)
**摘要**：利用重组RPA4蛋白进行体外实验，揭示其在乳腺癌细胞中过表达可干扰DNA末端切除修复，增强顺铂等DNA交联剂的细胞毒性，提示RPA4可能作为化疗增敏靶点。
3. **文献名称**：*Purification and structural analysis of recombinant RPA4: Insights into its role in telomere maintenance*
**作者**：Smith, J., et al. (2018)
**摘要**：优化了大肠杆菌表达系统获得高纯度RPA4重组蛋白，晶体结构分析表明其C端结构域与端粒单链DNA结合能力显著低于RPA2.可能解释其在端粒保护中的辅助功能。
---
**注意**：以上内容为基于领域知识的模拟生成，实际文献需通过PubMed、Google Scholar等平台检索关键词(如"RPA4 recombinant"、"RPA4 function")获取。
**Background of RPA4 Recombinant Protein**
Replication Protein A (RPA), a conserved heterotrimeric complex (RPA1. RPA2. RPA3), is essential for DNA metabolism, including replication, repair, and recombination. It stabilizes single-stranded DNA (ssDNA) intermediates and coordinates repair machinery. The RPA4 subunit, encoded by the *RPA3* paralog *RPA4* (or *RPA3L*), shares structural homology with RPA2 but exhibits distinct regulatory roles. RPA4 replaces RPA2 in an alternative RPA complex (aRPA), altering DNA-binding dynamics and cellular responses to genotoxic stress.
Recombinant RPA4 protein is engineered to study its unique functions. Produced via expression systems like *E. coli* or mammalian cells, it retains biochemical activity for ssDNA binding and protein interaction. Studies reveal that aRPA (containing RPA4) modulates DNA damage signaling pathways, potentially influencing cell cycle checkpoints and repair pathway choice (e.g., homologous recombination vs. non-homologous end joining). Its expression is upregulated in certain cancers, linking it to genomic instability and therapy resistance.
RPA4’s role in cancer biology and DNA repair mechanisms makes it a focus for translational research. Recombinant RPA4 enables in vitro assays to dissect its interactions with repair factors (e.g., ATR, RAD51) or screen inhibitors targeting RPA complexes. Additionally, it aids in exploring how aRPA fine-tunes stress responses, impacting cell survival or death decisions.
Despite progress, questions remain about RPA4’s tissue-specific regulation, post-translational modifications, and therapeutic potential. Its study bridges fundamental DNA repair mechanisms with applications in oncology and drug discovery, highlighting its dual significance in cellular biochemistry and disease contexts.
×
